Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotatug Vedotin and Epirubicin as Neoadjuvant Therapy for Sinonasal Adenoid Cystic Carcinoma
NCT07522879Phase 2Recruiting
- Sponsor
- Eye and ENT Hospital of Fudan University
- Start
- Apr 2026
- Primary completion
- Oct 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of becotatug vedotin in adenoid cystic carcinoma (ACC), sponsored by Eye and ENT Hospital of Fudan University. Started Apr 2026; status: recruiting.
02
Drugs
becotatug vedotin
03
Conditions
adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on NCT07522879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07522879.